RTI Surgical has a new commercial director

(Photo courtesy of RTI Surgical)

RTI Surgical today announced that it has appointed Chad Croasdale as chief commercial officer.

Croasdale has more than 20 years of commercial and financial experience in the medtech industry. He will oversee the tissue reconstruction company’s growth strategy and corporate development.

“We are pleased to welcome Chad to RTI. His extensive experience in commercial success will be invaluable as we continue to strengthen our position as the CDMO partner of choice in regenerative medicine, leveraging our unique portfolio of xenograft and allograft biomaterials to improve patient outcomes,” said President and CEO Olivier Visa in a press release.

Before joining the Alachua, Fla.-based company, Croasdale was president and chief commercial officer of 270Surgical. Before that, he spent more than 18 years at Stryker in roles of increasing responsibility, ultimately becoming vice president and general manager of Stryker Communications, Endoscopy, where he oversaw the communications business unit and led commercial, sales and R&D activities.

“I am excited to join RTI Surgical, a company with a strong reputation for commitment to quality, innovation and patients, and a clear growth strategy. I look forward to working with the team and our OEM partners to advance biomaterials and expand our reach to even more patients,” said Croasdale.